Cognetivity Neurosciences is developing an AI platform that utilizes patented rapid cognitive analysis technology for the early detection of cognitive impairment, dementia, and Alzheimer's disease. This platform offers a more accessible and cost-effective solution for accurate diagnosis, enabling timely intervention for patients.
Funding
Funding not disclosed
Founders
Product
Problem
Early detection of cognitive impairment, dementia, and Alzheimer's disease relies on accurate and accessible cognitive assessments. Traditional methods can be time-consuming, costly, and may not be readily available to all patients, hindering timely diagnosis and intervention.
Solution
Cognetivity Neurosciences is developing an AI-driven platform designed for the rapid assessment of cognitive function. The platform employs a patented cognitive analysis technology to identify subtle indicators of cognitive impairment, dementia, and Alzheimer's disease at an early stage. By offering a more accessible and cost-effective solution, the platform aims to improve diagnostic accuracy and enable earlier intervention for patients at risk. The technology facilitates frequent and widespread cognitive screening, leading to better patient outcomes and reduced healthcare costs.
Target Audience
The primary target audience includes healthcare providers, neurologists, geriatricians, and researchers involved in the diagnosis and management of cognitive disorders.
Features
- AI-powered cognitive assessment platform
- Patented rapid cognitive analysis technology
- Early detection of cognitive impairment, dementia, and Alzheimer's disease
- Accessible and cost-effective diagnostic solution